Kian Sadeghi
Founder & CEO, Nucleus Genomics. On 3 shows, 5 appearances. The Shows tab opens the full record on each.
founderexecutive@KianSadeghi5 ↗LinkedIn ↗mynucleus.com ↗
After leaving the University of Pennsylvania in 2021, Sadeghi founded Nucleus Genomics and raised over $30 million to offer whole-genome health and embryo screening. He is known for promoting consumer access to genetic optimization, screening IVF embryos and adult genomes for polygenic disease risks and traits.
3shows
5appearances
41statements
13resolved
10supported
2contradicted
77%fully supported
8said about them ↓ Everything Kian Sadeghi said on any show that made the record, most notable first. Each card names its show and opens the statement there.
Sadeghi: Nucleus is the first company to optimize embryos for IQ
“This is the first time a company has partnered with a couple who have optimized their embryos on the basis of intelligence.”
Sadeghi: Patients, not doctors, should use genetic data to select embryos
“We believe that every piece of information from cancer to IQ to schizophrenia belongs very thoughtfully in the hands of the patient, and the patient is the one, not the doctor, that the patient is the one that should pick their embryo.”
Nucleus software analyzes embryo DNA to predict IQ, cancer risk, and traits
“So usually parents have a couple viable embryos, and now they can actually take the raw DNA files of them, upload to Nucleus, and we'll give you analysis on everything from cancers, to IQ, to eye color, to hair color, to schizophrenia risk.”
Sadeghi: Falling IVF and sequencing costs will create genetically optimized children
“And so you're going to see the rapid decrease in cost of IVF combined with the rapid decrease in cost of sequencing A genome. These things are going to converge together to enable this just, this massive, massive new generation of parents having genetically op…”
Sadeghi: Future reproductive genomics platforms will both sequence and edit DNA
“Because eventually, you're not just going to be sequencing and analyzing DNA, You'll also probably be editing it as well.”
Sadeghi: The medical distinction between genetic diseases and traits is arbitrary
“From our perspective as a company, there's really no difference between diseases and traits. It's a false line in the sand that was drawn.”
Sadeghi: 23andMe's genetic testing is ineffective for disease risk assessment
“Toilet meat technology missing millions and millions of genetic markers. Effectively, it's not actually useful for any really disease risk assessment.”
Sadeghi: Scientific research already links genetics directly to intelligence
“At the frontier of science, we do already have associations with genetics and intelligence, and we really believe in giving these insights to customers.”
Sadeghi: Study shows over 50% of people accept genetic optimization for IQ
“There was actually a really good study that was done asking couples about genetic optimization, which is, you know, what's their perspective on it. And in the study, it said over 50% of people said genetic optimization for something like IQ is fine. And then I…”
Sadeghi: Embryo selection can only shift IQ by a few points
“Embryo selection will always be a relative optimization, right? IQ can explain a couple IQ points, right? Height, you can, you know, explain a couple inches, but principally if you, the most important kind of the ingredients for your embryos comes from mom and…”
Sadeghi: Embryo selection can dramatically reduce Alzheimer's and cancer risks
“You can still dramatically reduce the baby's risk, for example, for something like Alzheimer's, Which is then strongly associated with longevity or breast cancer or coronary artery disease, which are the top killers in the United States today.”
Sadeghi: Genomic sequencing, analysis, and editing will create a trillion-dollar industry
“And when you think about the next 10 years, you know, as I alluded to earlier, sequencing technology is kind of cheaper, analysis is kind of cheaper, understand the genome is going to dramatically increase, and genome editing is going to become much cheaper. A…”
Sadeghi: 23andMe cannot develop drugs using microarray genetic data
“They really viewed data gathering as a means to make drugs, but because it's such a small sliver of your DNA, you actually can't really make drugs off of it”
Sadeghi: 23andMe is not HIPAA compliant
“One of the most shocking things about 23 means is it's actually not HIPAA compliant, right? It doesn't follow the gold standard clinical regulations that ensure your data is safeguarded.”
Sadeghi predicts a whole-genome consumer health behemoth within a decade
“I really do think in the next decade, You're going to see the rise of a consumer health behemoth, and that consumer health behemoth is going to have a whole genome, the entire of someone's DNA at its foundation, and it's going to impact not just someone's heal…”
Sadeghi: Genetics alone can never predict IQ due to 50% environmental factor
“You can't. From genetics predicts someone's IQ. And actually what a lot of people don't realize is you will never be able to. And the reason for that is because 50% of intelligence is environmental. The other 50% is genetic.”
Sadeghi predicts a trillion-dollar platform integrating all personal health data
“I think we're in the age where there will be a trillion dollar consumer healthcare business, and that business is going to be integrated in the entirety of someone's health data on the platform.”
Sadeghi: Genome analysis technology will be as transformative as AI
“I think genetic testing technology and analysis technology, genome technology, if you will, It's going to be as powerful as artificial intelligence. Artificial intelligence is ultimately a tool, and it's a tool that's going to, I think, be most consequential i…”
Sadeghi: Nucleus Genomics Is Years Ahead in Replacing 23andMe
“You go from Blockbuster to Netflix, you go from, you know, Blackberry to the iPhone, you go from MySpace to Facebook, and now you're going from 23 and Me to Nucleus Genomics, right? The industry is wide open, Nucleus is years ahead, and we're going to seize th…”
Sadeghi: Nucleus Genomics is exploring an acquisition of 23andMe assets
“I think one thing this nucleus actively is looking into right now, considering whether it makes sense, you know, earlier, I'm sure you remember, you know, we explored the possibility of acquiring and we're looking into right now whether that would make sense t…”
Sadeghi: Nucleus IQ benchmarks against genetic cohorts, rather than predicting IQ
“Nucleus IQ, the function of it is not to predict your IQ score. The way it works is it basically tells you people with similar genetics to you, how they tend to score on an IQ test.”
Sadeghi predicts Nucleus will sequence 500,000 whole genomes by 2026
“I think we can actually, I think two years from now, we can get half a million samples. Two years from today, I think we could do that.”
Sadeghi: 23andMe Offers Superficial Traits Despite Massive Advances in Genetics
“There's all this research, there's all these insights, there's all this innovation, right? But we're stuck with Do you like chocolate or not from 23 and me? Like, what's going on here, right?”
Sadeghi Cold-Emailed the Future Nucleus CSO 50 Questions Under a Pseudonym
“I emailed, under pseudonym, just to be honest with you, under pseudonym, our, again, current chief scientific officer, and I asked him, like, you know, 50 questions, right? And he was kind enough to actually, he answered all the questions.”
The other half of the tape: Kian Sadeghi's own voice is left out of every number here. Other people bring the name up 8 times in 2 episodes across the shows. every mention, with the transcript →
Who brings them up most John Coogan 1
Every mention by year
tap a year for its mentions
TBPN 8
One line per show, most statements first. The link opens Kian's full record on that show: the calibration, argument clarity, speaking style and every statement made there.
| Show | Role there | Eps | Statements | Record | |
|---|---|---|---|---|---|
 SOURCERYLEDGER | Founder & CEO, Nucleus Genomics | 2 | 23 | 70% 7/10 | full record on Sourcery → |
 FOUNDER'S JOURNALLEDGER | Founder & CEO, Nucleus Genomics | 1 | 9 | 100% 1/1 | full record on Founder's Journal → |
| TBPNLEDGER | Founder & CEO, Nucleus Genomics | 2 | 9 | 100% 2/2 | full record on TBPN → |